BC Innovations | Aug 22, 2019
Distillery Therapeutics

Pretreatment with STAT1 activators, IL-10 blocker to improve response to checkpoint inhibitors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; mesothelioma; renal cancer Activating STAT1 and blocking IL-10 prior to checkpoint inhibitor administration could improve efficacy in patients with mesothelioma, melanoma and other cancers. High intratumoral expression of a gene...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Encephalitis Mouse studies suggest TLR3 inhibitors could help treat herpes simplex virus type 1 (HSV-1)-induced encephalitis. In a mouse model of HSV-1 encephalitis, an anti-TLR3 antibody decreased CNS viral levels and increased survival compared...
BC Week In Review | Jul 20, 2018
Financial News

Provention raises $64M IPO

Autoimmune and infectious disease company Provention Bio Inc. (NASDAQ:PRVB) raised $63.9 million on July 19 through the sale of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty &...
BC Extra | Jul 20, 2018
Financial News

Provention raises $64M IPO

Autoimmune and infectious disease company Provention Bio Inc. (NASDAQ:PRVB) raised $63.9 million on Thursday through the sale of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty & Co....
BC Week In Review | May 11, 2018
Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed on May 9 to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed...
BC Extra | May 10, 2018
Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies...
BioCentury | Sep 29, 2017
Emerging Company Profile

Interception springboard

Provention Bio Inc. is starting off with the benefit of experience gained at Johnson & Johnson ’s Janssen Research & Development LLC unit, as well as disease interception assets generated in the pharma’s immunology group....
BC Week In Review | Sep 22, 2017
Company News

Provention reveals Janssen products

Provention Bio Inc. (Lebanon, N.J.), a newco pursuing autoimmune and inflammatory disease therapies, disclosed details regarding two in-licensed programs from the Janssen unit of Johnson & Johnson (NYSE:JNJ). Provention holds exclusive, worldwide rights to PRV-6527...
BC Extra | Sep 21, 2017
Company News

Provention details pipeline

Provention Bio Inc. (Lebanon, N.J.), a newco pursuing autoimmune and inflammatory disease therapies, disclosed details on Thursday regarding two in-licensed programs from the Janssen unit of Johnson & Johnson (NYSE:JNJ). Provention holds exclusive, worldwide rights...
BC Innovations | Mar 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Bladder cancer; head and neck cancer; lung cancer Mouse studies suggest inhibiting TLR3 , TLR7 and TLR9 could help treat bladder, head and neck, and lung cancers. In mouse models of bladder and lung cancers,...
Items per page:
1 - 10 of 94